Immune Response and Durability of Human Papillomavirus Antibodies in Vaccinated Adolescents After Hematopoietic Stem Cell Transplantation: A Pilot Study

Immunogenicity of Quadrivalent Human Papillomavirus Vaccine in Adolescents after Hematopoietic Stem Cell Transplant: A Pilot Study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240825001

Enrollment

Registered

2024-08-25

Start date

2024-07-25

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunogenicity of two dose quadrivalent HPV vaccine in Adolescent after hematopoietic stem cell transplant. hematopoietic stem cell transplant, quadrivalent HPV vaccine, Immunogenicity

Interventions

2 doses of Quadrivalent HPV vaccine at 0,6 month

Experimental Biological/Vaccine

quadrivalent HPV vaccine

Eligibility

Sex/Gender

All

Age

9 Years to 15 Years

Inclusion criteria

Inclusion criteria: 1.Post-HSCT pediatric patients aged 9-15 years 2.Post-HSCT period more than 1 year 3.Out of immunosuppressive drug more than 6 month 4.No history of rituximab use post-HSCT period

Exclusion criteria

Exclusion criteria: 1.Previous HPV vaccination post-HSCT (Bivalent, Quadrivalent, Nonavalent) 2.History of sexual activity 3.Receipt of blood product or immunoglobulin within 3 months before study 4.Severe allergic reaction to a vaccine component or following a prior dose 5.Severe allergy to yeast

Design outcomes

Primary

Measure	Time frame
seropositive rate 1 month after second dose of vaccine Anti-HPV16 L1 IgG / ELISA , Anti-HPV18 L1 IgG / ELISA	—

Secondary

Measure	Time frame
adverse event after vaccination (eg. fever, pain, rash, anaphylaxis) 30 minutes , 48 hours,7 days after vaccination interview	—

Countries

Thailand

Contacts

Public ContactBenjaporn Wangviboonchai

Faculty of Medicine Ramathibodi hospital, Mahidol University

benspywang@gmail.com0875576265

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026